| |
[摘要]：Cortisol and the glucocorticoid receptor (GR) signaling pathway has been linked to the development of diabetes and metabolic syndrome. In vivo, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSDI) catalyzes the conversion of inactive cortisone to its active form, cortisol. Existing clinical data have supported 11 beta-HSDI as a valid therapeutic target for type 2 diabetes. In our research program, (R)-1,1,1-trifluoro-2-(3-((R)-4-(4-fluoro-2- (trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)propan-2- ol (HSD-016) was discovered to be a potent, selective, and efficacious 11 beta-HSDI inhibitor and advanced as a clinical candidate. Herein, a reliable and scalable synthesis of HSD-016 is described. Key transformations include an asymmetric synthesis of a chiral tertiary alcohol via Sharpless dihydroxylation, epoxide formation, and subsequent mild reduction. This route ensured multikilogram quantities of HSD-016 necessary for clinical studies. |
|
